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Summary.-Good immunoprotection was afforded by A9/SEWA somatic hybrid
cells in the C3H mouse/C3H Py tumour system, confirming results previously
obtained in the A.SW mouse/SEWA tumour system. However, in this study the
immunogenicity decreased with increasing serial subculture of the hybrid line and
concomitant chromosome loss.
WE HAVE previously shown the in-
teresting occurrence of anti-tumour im-
munization with somatic hybrid cells
(Favre, Carcassonne and Meyer, 1974a).
In these former experiments, we used
the A.SW mouse/polyoma induced SEWA
tumour system and protected by im-
munization with A9/SEWA hybrid cells.
However, though we could demonstrate
the presence of the tumour antigens
characteristic of polyoma virus in these
hybrid cells (Favre et al., 1974b), wenoticed
that the transplantation antigen was
gradually lost during in vitro passaging.
This loss does not appear to be fortuitous
since two different lines derived from the
same hybrid parent displayed the same
evolution. Evidently any clinical use of
hybrid cells would presuppose the stability
of such cells. We therefore describe here
fturther experiments using the comple-
mentary H-2k system (C3H mouse/C3H
Py solid tumour), where we tried to
assess the protective effect of the A9/
SEWA hybrid line as a function of
increasing subculture.
MATERIALS AND METHODS
Hybrid cells. The A9/SEWA hybrid cell
line has been fully described elsewhere
14)
(Harris et al., 1969). It bears both the
H-2s and H-2k histocompatibility loci. For
this work, 2 series of A9/SEWA cultures,
P and T, were used. The difference between
these 2 series is that, on reception in our
laboratory, the T series was already at
a more advanced level of subculture than the
P series.
Tumour cells-.The C3H-Py line was
obtained by in vitro transformation of
secondary C3H mouse embryo cultures by
polyoma virus (Favre and Meyer, 1972).
The tumour challenge was effected by
means of a dorsal, subcutaneous injection
of 103 C3H-Py cells. Morphological and
cytogenetic verification that some tumours
observed in each group were C3H-Py sarco-
mata was carried out systematically.
Polyoma virus. The small plaque Toronto
strain of polyoma virus grown in secondary
mouse embryo cultures was used (Dulbecco,
1961).
Mice.-22 month old inbred C3H mice,
bred in our laboratories, were used.
Immunization schedule.-Subcutaneous
dorsal injections of 106 A9/SEWA hybrid
cells were administered 21, 14 and 7 days
before the tumour challenge. A control
group received 3 injections of 107 PFU
polyoma virus following the same time
schedule.
Karyology.-The karyotypes were per-
formed as previously described (Meyer,
Berebbi and Klein, 1974).R. FAVRE, Y. CARCASSONNE AND G. MEYER
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TABLE I.-Immunoi
the First I
Immunization
A9/SEWA-P
42nd, 47th, 49th
subculture
A9/SEWA-T
82nd, 83rd, 85th
subculture
Polyoma virus
Non-immunized controls
The mice were immu
before challenge with 10
H.S. Highly significa
N.S. Non-significant.
TABLE II.-Immunc
the Second
Immunization
A9/SEWA-P
30th, 31st, 33rd
subculture
A9/SEWA-P
46th, 47th, 48th
subculture
A9/SEWA-P
61st, 62nd. 63rd
subculture
A9/SEWA-T
92nd, 96th, 97th
subculture
A9/SEWA-T
144th, 147th, 149th
subculture
Polyoma virus
Non-immunized controls
The mice were immi
before challenge with 101
H.S. Highly significa
S. Significant at 0
N.S. Non-significant
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By the 46th passage the A9/SEWA-P
cells afforded less protection and practic-
ally none at all by the 61st passage.
) and the polyoma DISCUSSION
DUp on the one hand We had previously reported that
inized by cells of the (Favre et al., 1974) in the A.SW mouse/
the non-immunized SEWA tumour system, good immuno-
other. protection was obtained by injection of
iperiment (Table II), A9/SEWA cells from " P " (30th) and
the protective effect T " (60th) passages of this hybrid.
Contrary to this, we found that in the
protection Observed in C3H mouse/C3H Py tumour system the
F.xperiment immunogenicity of the hybrid cells de-
creased with successive subculture.
bearing animals/ This loss could be related to chromo-
No. ofanimals some instability and possibly chromosome
3/15 20% H.S. loss in these hybrids. By consecutive
cytogenetic studies, chromosome loss dur-
15/15 100% N.S. ing subculture has been demonstrated
in the A91SEWA line (Meyer et al., 1974).
0/15 0% H.S. Our results confirm that there is a loss
15/15 100% of chromosomes during subculture of
both P and T A9/SEWA strains (Berebbi,
inized 21, 14 and 7 days
3 C3H-Py cells. personal communication). However, it
unt at 0 01 level. has not been possible to show a direct
relationship between the loss of any one
protection Observed in specific chromosome and the loss of
Experiment transplantation immunogenicity. In any
case, it seems that the capacity of im-
bearing animals/ munoprotection and thence the presence
No. ofanimals of polyoma virus specific transplantation
0/10 0% H.S. antigen is not indispensable for the
survival of the hybrid in vitro nor closely
5/14 35% S. related to an indispensable function.
It has been hoped (Parkman, 1974)
9/15 60% N.S. that somatic cell hybrids could be used
in immunotherapy. Our results seriously
14/15 93% N.S. compromise such a clinical application
since the utilization of such treatments
is obviously linked to the stabilitv of the
11/15 73% N.S. hybrid cell and the expression of the
tumour transplantation antigen. If hy-
2/15 13% H.S. brid cells are to be used, it will be neces-
15/15 100% sary to ascertain whether the tumour
unized 21, 14 and 7 days associated antigens (especially the trans-
3 C3H-Py cells. plantation antigens) are still present at nt at 0501 level, each time of subculture. We are at
present testing various in vitro techniques
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for detecting the expression of these
functions.
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